This panel will explore areas where digital technology has had the greatest impact and where it has fallen short of expectations. Panel members will provide insight on likely areas of growth and investment in the coming year.
Read More
Read More
There have been more than 20 years of bipartisan policy change in state and federal government that are fundamentally changing America’s healthcare landscape. These changes have created a new level of competition and innovation that is transforming care delivery, organization and speed of change.
Read More
Read More
Biopharmaceutical innovation in oncology continues to garner premium pricing in the US healthcare system. While many of these products provide evidence of transformational health impacts on patients’ lives during clinical development, uncertainty often exists around how promising efficacy and safety clinical data will translate into real-world benefits and risks. Long -term survival data, durability of effectiveness, and heterogeneity of outcomes across diverse sub-populations represent some of the common evidence gaps at launch.
Read More
Read More
How do we mobilize cancer moonshot with philosophical, logistical and economic considerations? A conversation representing multi-disciplinary perspectives beyond oncology, and two experts that represent the practice of medicine and the practice of economics. We will explore the implications of how we measure value, what we owe the future, what we have done right and what might go wrong. Is it a consensus opinion that brings innovation to fruition for the benefit of patients? What are we missing and are we speaking past each other as we confront the limited resources we have today and the promise we owe the future in cancer care.
Read More
Read More
The Inflation Reduction Act signed into law in August 2022, resulted in groundbreaking changes in the U.S. pharmaceuticals industry that will happen over the next 5 years; 2026 to 2029. The two main components of the legislation aim to reform Medicare's drug-pricing policy: price negotiations and higher inflationary cap price.
Read More
Read More
The arrival of cell and gene therapy has challenged the regulatory, payment and care delivery systems in oncology. Health policy, government and industry experts will discuss breakthrough technologies—from development to dissemination—and how to prepare and support patients who need them.
Read More
Read More
Revenue Cycle Management is evolving as contracting into the future will require more and more interoperability of clinical and as the industry moves ahead and adopts more Value-Based Contracts. The complexity of system and process requirements are growing, and this panel will discuss the future system and business requirements ahead and how all stakeholders need to prepare for the future.
Read More
Read More
Multiple previously published studies have reported the benefits of integrating ePROs into routine care for cancer patients, including improvements in quality of life, symptom control, reductions in ED visits and overall survival. Through ePRO programs, cancer patients can actively participate in their care by providing insights on their progress and symptoms.
Read More
Read More
The Inflation Reduction Act (IRA) of 2022 contains several provisions that could have a material impact on the US health insurance industry over the short and intermediate terms. This is particularly because it relates to the extension of Affordable Care Act (ACA) subsidies (until 2026), as well as the stability and potential growth of the ACA market as higher subsidies play a significant role in supporting the ACA market throughout the country.
Read More
Read More
This session will address what cancer care practices are doing in regards to value-based agreements.
Read More
Read More